Ray Dorsey, MD, MBA David M. Levy Professor in Neurology, University of Rochester Medical Center Director, CHET and Center for Health and Technology University of Rochester Medical Center Rochester, NY
Daniel Kremens, MD, JD Associate Professor of Neurology, Sidney Kimmel Medical College at Thomas Jefferson University Co-Director of the Parkinson’s Disease and Movement Disorders Division Neurology Clerkship Director, Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia, PA
Albert Einstein CCME Reviewer David Myland Kaufman, MD Professor, The Saul R. Korey Department of Neurology Professor, Department of Psychiatry and Behavioral Sciences Albert Einstein College of Medicine Bronx, NY
Approximately 1 million US adults have Parkinson’s disease (PD), a progressive neurodegenerative movement disorder that affects motor and cognitive function and significantly impairs quality of life. Treatment of advancing disease can be complicated because clinicians must manage both motor deterioration and nonmotor symptoms. Long-term treatment carries significant complications that can exacerbate disease complications that will develop as the patient worsens. Novel formulations of therapies and advances in surgical options can provide additional resources for clinicians to improve patient outcomes with progressing disease.
This activity is jointly provided by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.
This activity is intended for neurologists, movement disorder specialists, and other clinicians with a neurology specialty including PAs, NPs, and RNs managing patients with PD.
Upon completion of this educational activity, the participant should be able to:
Apply patient-centered care strategies to identify optimal treatment for individual patients with moderate or advanced PD.
Describe recent new evidence for the benefits and risks of treatment options for motor symptoms in advanced PD.
The “Conflict of Interest Disclosure Policies” of Albert Einstein College of Medicine of Yeshiva University require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine of Yeshiva University (Einstein) also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.
Dr. Dorsey has disclosed the following:
Research support: National Institutes of Health, National Sciences Foundation, David Phinney Foundation, Patient Centered Outcomes Research Institute, Biogen Idec, Prana Biotechnology, Auspex Pharmaceuticals, Michael J. Fox Foundation, Huntington Study Group, Sage Bionetworks
Consultant: Amgen, Avid Radiopharmaceuticals, Clintrex, Lundbeck, Medtronic, National Institute of Neurological Disorders and Stroke, Transparency Life Sciences, MC10, Inc., F. Hoffman-La Roche, Ltd., Shire
Patent: product related to telemedicine and neurology
Dr. Kremens has disclosed the following:
Consultant: AbbVie, Chelsea Therapeutics, Impax, Lundbeck, Merz, US WorldMeds, Teva, UCB
Speakers Bureau: Lundbeck, Merz, US WorldMeds, Teva, UCB
Research Support: Avid Radiopharmaceuticals, Biotie, Civetas
Dr. Kaufman has disclosed the following:
Royalties: Wolters Kluwer, Elsevier
Honoraria: United States Navy
Kelly Andrzejewski, DO, PhD, provided editorial input. She has nothing to disclose.
The staff of the Center for Continuing Medical Education at Albert Einstein College of Medicine and Montefiore Medical Center and MCM Education have nothing to disclose.
Gena Dolson, MCM Education Senior Medical Writer, has nothing to disclose. Credit Statements
ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
ACCME CREDIT DESIGNATION STATEMENT: Albert Einstein College of Medicine of Yeshiva University designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
Credit is awarded to participants who score 80% or better on the post-test.
The online activity will take approximately 30 minutes to complete. Commercial Support Statements
This activity is supported by independent educational grants from Teva Pharmaceuticals, UCB, and Lundbeck.
Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education and MCM Education.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, MCM Education, Teva Pharmaceuticals, or UCB. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
Data collected in the surveys and polling questions will be used to guide future educational activities and will remain anonymous.